Experts explore the socioeconomic impact of CSCC and BCC, and which late-stage patients will derive the greatest benefit from hedgehog inhibitors, immunotherapies, and other emerging treatments.
Experts discuss optimal utilization of CSCC and BCC staging systems and risk stratification to guide treatment decisions and the appropriate timing for active surveillance vs intervention.
Key opinion leaders emphasize the role of coordinated care between dermatologists and oncologists in monitoring and managing adverse events related to immunotherapy in CSCC and BCC.